Dianthus Therapeutics, Inc.
DNTH Healthcare
₹ 82.27
3.34%
Live Market Data
Market Cap₹ 436 Cr.
Current Price₹ 82.27
High / Low₹88.02 / 13.37
Stock P/E0.0
Book Value₹11.4
Dividend Yield0.00 %
ROCE-0.2 %
ROE-0.4 %
About Company
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Industry Segment
Biotechnology
Price Chart
Loading Chart...
Technical Analysis
Technical Outlook
Short TermBullish
Mid TermBullish
Long TermNeutral
Resistance₹80.21
Support₹21.32
Valuation Check
Fair Value Assessment
Overvalued
Research Reports
AbbVie Earnings: Maintaining Our FVE as Skyrizi Holds Steady Share Despite Competition
Argus Quick Note: Weekly Stock List for 03/09/2026: AI Series 2: Healthcare and AI
Quarterly Results
| Particulars | Sept 25 | Jun 25 | Mar 25 | Dec 24 | Sept 24 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0.04 | 0.02 | 0.12 | 0.13 | 0.22 |
| Net Income (Cr) | -3.68 | -3.16 | -2.95 | -2.84 | -2.52 |
| EPS (₹) | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 |
Annual Profit & Loss
| Particulars | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue (Cr) | 0.62 | 0.28 | 0.64 | 0.15 |
| Operating Exp (Cr) | 10.81 | 5.1 | 3.61 | 1.46 |
| Net Income (Cr) | -8.5 | -4.36 | -2.85 | -1.31 |
| EPS (₹) | -2.55 | -8.45 | -1.92 | -0.88 |
Balance Sheet
| Particulars | Sept 25 | Jun 25 | Mar 25 | Dec 24 | Sept 24 |
|---|---|---|---|---|---|
| Total Assets (Cr) | 57.74 | 32.61 | 34.86 | 37.4 | 35.42 |
| Total Liabilities (Cr) | 3.1 | 2.3 | 2 | 2.15 | 1.64 |
| Total Equity (Cr) | 54.65 | 30.31 | 32.86 | 35.25 | 33.79 |
Key Ratios Fundamentals
Valuation
P/E Ratio (TTM)
-Forward P/E
-16.10PEG Ratio
-Price / Book
7.21EV / EBITDA
-17.64Profitability
ROE
-38.38%ROA
-24.58%Profit Margin
-Operating Margin
-24486.27%Liquidity & Debt
Current Ratio
13.32Quick Ratio
13.16Debt / Equity
0.28Total Cash (Cr)
40.43Price Statistics
Beta
1.2452W High
88.0252W Low
13.37Dividend Yield
-Pattern Unavailable
Detailed shareholding breakdown is not currently provided by the exchange.